{"id":534486,"date":"2021-09-05T06:18:09","date_gmt":"2021-09-05T10:18:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-updates-data-from-its-phase-1-trial-for-liver-cancer-at-ilca-showing-clinical-benefit\/"},"modified":"2021-09-05T06:18:09","modified_gmt":"2021-09-05T10:18:09","slug":"adaptimmune-updates-data-from-its-phase-1-trial-for-liver-cancer-at-ilca-showing-clinical-benefit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-updates-data-from-its-phase-1-trial-for-liver-cancer-at-ilca-showing-clinical-benefit\/","title":{"rendered":"Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit"},"content":{"rendered":"
\n

– One complete response, and a disease control rate of 64% with stable disease for \u226516 weeks in two patients, as of the data cutoff –<\/p>\n

– Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET –<\/p>\n

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc\u00a0(Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA.<\/p>\n

\u201cWe have seen significant antitumor activity with this first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease,\u201d said Elliot Norry, Adaptimmune\u2019s Chief Medical Officer. \u201cWe reported a complete response in one patient, and tumor reductions with stable disease that has lasted more than 16\u00a0weeks in two patients as well as disease control in most patients at the target dose. We are continuing the expansion phase and will update when new data becomes available.\u201d<\/p>\n

\u201cDespite the recent advances, we need more and better systemic therapies for liver cancer,\u201d said Dr. Bruno Sangro of Clinica Universidad de Navarra. \u201cThe first results from this cell therapy trial are of great interest since they indicate obvious antitumor activity in some patients. This treatment has generally been safely applied even to cirrhotic patients.\u201d<\/p>\n

\n Oral Presentation Today at ILCA<\/strong>
\n
Dr. Bruno Sangro presented data from Cohort 3 and the expansion phase of the ADP-A2AFP Phase 1 trial during an oral presentation today at ILCA. A replay will be available through the congress web site.<\/p>\n

\n Topline results from the ADP-A2AFP Phase 1 trial as of the April 5, 2021 data cutoff<\/strong>
\n
\n
\n Efficacy <\/em>
\n <\/strong>\n <\/p>\n